Aranesp (darbopoetin alfa) For Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

Summary View

Sections Modified

PRECAUTIONS

• Hematology
• Patients Transitioning to Dialysis

ADVERSE REACTIONS

• Chronic Renal Failure Patients
  • Adult Patients
    • Table 2
    • Table 3
  • Pediatric Patients

 

Label approved 05/05/2008 is not available on Drugs@FDA